Philippe Musette

Université Sorbonne Paris Nord — France

Medicine · Health Sciences

35h-index6.4kcitations136works5.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Autoimmune Bullous Skin Diseases(46), Urticaria and Related Conditions(37), Coagulation, Bradykinin, Polyphosphates, and Angioedema(26), Drug-Induced Adverse Reactions(25), T-cell and B-cell Immunology(20)

Publications136 total

003 Unveiling the phenotypic landscape of autoreactive Dsg3+ B Cells and CD83 pathway in pemphigus vulgaris: Towards new targets in a paradigm of autoimmunity
Journal of Investigative Dermatology·2025
Bridging the gap in autism care: A qualitative analysis of policies, practices, and family experiences
Public Health·2025
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris
JAMA Dermatology·2025· 3 cited
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy
JAMA Dermatology·2024· 18 citedOpen Access
Variability of viral reactivations during recurrence of DRESS
Australasian Journal of Dermatology·2023· 1 citedOpen Access
Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients
Frontiers in Immunology·2022· 18 citedOpen Access
Autoimmune Pemphigus: Latest Advances and Emerging Therapies
Frontiers in Molecular Biosciences·2022· 33 citedOpen Access
Pemphigoïdes des muqueuses traitées par rituximab : étude rétrospective monocentrique chez 109 patients avec suivi à long terme
Annales de Dermatologie et de Vénéréologie - FMC·2021
Updated French guidelines for the therapeutic management of bullous pemphigoid
Annales de Dermatologie et de Vénéréologie·2021· 17 cited
Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
Frontiers in Immunology·2021· 14 citedOpen Access
Incidence et pronostic de la COVID-19 chez les malades atteints de maladie bulleuse auto-immune
Annales de Dermatologie et de Vénéréologie·2020· 2 citedOpen Access
Clinical and Biological Activity of Rituximab in the Treatment of Pemphigus
Immunotherapy·2020· 8 cited
Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Scientific Reports·2019· 6 citedOpen Access
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect
British Journal of Dermatology·2019· 91 citedOpen Access
Editorial: Skin Blistering Diseases
Frontiers in Medicine·2019· 1 citedOpen Access
A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGFα-Mediated Recruitment of Neutrophils
Immunity·2019· 60 citedOpen Access
B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Scientific Reports·2019· 36 citedOpen Access
Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués
Annales de Dermatologie et de Vénéréologie·2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference
Frontiers in Medicine·2018· 26 citedOpen Access
Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients
Journal of Investigative Dermatology·2018· 9 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

P. Joly(13), Gabriel Gachelin(9), Sébastien Calbo(8), Philippe Kourilsky(8), M. D’Incan(7), C. Bédane(6), Baptiste Janela(6), Maud Maho‐Vaillant(5), Frédérique Caillot(5), Philippe Bernard(5), E. Delaporte(5), Danièle Gilbert(5), Serge Jacquot(5), François Tron(5), D Picard(5), Louis Dubertret(5), Jean‐David Bouaziz(4), F. Caux(4), Jacques Bénichou(4), Michael Hertl(4)